MCID: SLP001
MIFTS: 54

Sleeping Sickness

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 52 53 58 3 15
African Trypanosomiasis 12 74 58 3 15 71 32
Trypanosomiasis, Human East-African 52
Human African Trypanosomiasis 17
African Sleeping Sickness 12
Trypanosomiasis, African 43
Trypanosomiasis African 54

Characteristics:

Orphanet epidemiological data:

58
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD9CM 34 086.5
MeSH 43 D014353
NCIt 49 C84541
SNOMED-CT 67 27031003
ICD10 32 B56 B56.9
MESH via Orphanet 44 D014353
ICD10 via Orphanet 33 B56.0 B56.1 B56.9
UMLS via Orphanet 72 C0041228
Orphanet 58 ORPHA3385
UMLS 71 C0041228

Summaries for Sleeping Sickness

NINDS : 53 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to trypanosomiasis and leishmaniasis. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are African trypanosomiasis and Glutathione metabolism. The drugs Ornithine and Nifurtimox have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness", is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Wikipedia : 74 African trypanosomiasis, also known as African sleeping sickness or simply sleeping sickness, is an... more...

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 31.7 ODC1 NOS2 IL6 IL10 HPR HP
2 leishmaniasis 31.0 SRM PGD ODC1 NOS2 IL6 IL10
3 chagas disease 30.9 SRM ODC1 NOS2 IL6 IL10 GSR
4 orchitis 30.7 IL6 IL10 H2AC18
5 deficiency anemia 30.7 TF IL6 HP H2AC18 GSR
6 visceral leishmaniasis 30.7 PGD NOS2 IL10
7 acquired immunodeficiency syndrome 30.6 NOS2 IL6 IL10 APOA1
8 filariasis 30.5 NOS2 IL6 IL10
9 exanthem 30.5 IL6 IL10 H2AC18
10 parasitic helminthiasis infectious disease 30.5 IL6 IL10 H2AC18
11 dysentery 30.5 TF IL6 IL10 HP H2AC18
12 mycobacterium tuberculosis 1 30.4 PRODH IL10 H2AC18 GAPDH
13 bacterial infectious disease 30.4 PRODH IL6 IL10 H2AC18
14 malaria 30.3 SRM ODC1 NOS2 IL6 IL10 HP
15 nervous system disease 30.3 PRODH NOS2 IL6 H2AC18
16 parasitic protozoa infectious disease 30.3 PRODH IL6 IL10 HP H2AC18 APOL1
17 toxoplasmosis 30.3 NOS2 IL6 IL10
18 placenta disease 30.2 PRODH IL6 H2AC18
19 central nervous system disease 30.1 PRODH NOS2 IL6 H2AC18
20 eye disease 30.1 PRODH IL6 IL10 H2AC18 GAPDH APOA1
21 trypanosomiasis, human west-african 11.4
22 von economo's disease 11.4
23 eastern equine encephalitis 11.2
24 spotted fever rickettsiosis 10.6 NOS2 IL10
25 castleman disease 10.6 IL6 IL10 CXCL13
26 eye lymphoma 10.6 IL6 IL10 CXCL13
27 neurosyphilis 10.6 IL10 CXCL13
28 bronchopneumonia 10.6 IL6 IL10 HP
29 endometrial disease 10.6 IL6 IL10 HP
30 trachoma 10.6 IL6 IL10 HP
31 autoimmune disease of blood 10.6 IL6 IL10 HP
32 syndromic x-linked intellectual disability snyder type 10.6 SRM ODC1 AMD1
33 rheumatic fever 10.6 IL6 IL10 HP
34 acute transverse myelitis 10.6 IL6 IL10 APOA1
35 transverse myelitis 10.6 IL6 IL10 APOA1
36 anhaptoglobinemia 10.6 HPR HP
37 endometritis 10.6 IL6 HP CXCL13
38 bacterial sepsis 10.6 NOS2 IL6 IL10
39 central nervous system lymphoma 10.6 IL6 IL10 CXCL13
40 vaginal disease 10.6 IL6 IL10 H2AC18
41 listeriosis 10.6 IL6 IL10 H2AC18
42 herpangina 10.6 IL6 IL10 H2AC18
43 splenic disease 10.6 IL6 IL10 H2AC18
44 coccidiosis 10.6 IL6 IL10 H2AC18
45 anus disease 10.6 IL6 IL10 H2AC18
46 extrinsic allergic alveolitis 10.6 IL6 IL10 HP
47 rectal disease 10.6 IL6 IL10 H2AC18
48 autoimmune disease of endocrine system 10.6 IL6 IL10 H2AC18
49 spinal cord disease 10.6 IL6 IL10 H2AC18
50 colonic benign neoplasm 10.6 ODC1 IL6 H2AC18

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Human phenotypes related to Sleeping Sickness:

58 (show top 50) (show all 87)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 Frequent (79-30%)
2 hepatomegaly 58 Frequent (79-30%)
3 behavioral abnormality 58 Occasional (29-5%)
4 hallucinations 58 Very rare (<4-1%)
5 seizures 58 Very rare (<4-1%)
6 neurological speech impairment 58 Occasional (29-5%)
7 sleep disturbance 58 Very frequent (99-80%)
8 dyskinesia 58 Occasional (29-5%)
9 reduced consciousness/confusion 58 Occasional (29-5%)
10 muscle weakness 58 Frequent (79-30%)
11 vomiting 58 Occasional (29-5%)
12 fatigue 58 Frequent (79-30%)
13 renal insufficiency 58 Occasional (29-5%)
14 gait disturbance 58 Occasional (29-5%)
15 cranial nerve paralysis 58 Occasional (29-5%)
16 arrhythmia 58 Very rare (<4-1%)
17 irritability 58 Occasional (29-5%)
18 weight loss 58 Frequent (79-30%)
19 pruritus 58 Frequent (79-30%)
20 arthralgia 58 Occasional (29-5%)
21 tremor 58 Occasional (29-5%)
22 congestive heart failure 58 Very rare (<4-1%)
23 pericarditis 58 Very rare (<4-1%)
24 anxiety 58 Occasional (29-5%)
25 alopecia 58 Occasional (29-5%)
26 jaundice 58 Occasional (29-5%)
27 third degree atrioventricular block 58 Occasional (29-5%)
28 ventriculomegaly 58 Occasional (29-5%)
29 paresthesia 58 Occasional (29-5%)
30 involuntary movements 58 Occasional (29-5%)
31 insomnia 58 Frequent (79-30%)
32 fasciculations 58 Occasional (29-5%)
33 myocarditis 58 Very rare (<4-1%)
34 conjunctivitis 58 Occasional (29-5%)
35 abnormality of the menstrual cycle 58 Occasional (29-5%)
36 keratitis 58 Occasional (29-5%)
37 gynecomastia 58 Occasional (29-5%)
38 headache 58 Frequent (79-30%)
39 abnormality of the nervous system 58 Very frequent (99-80%)
40 abnormality of the endocrine system 58 Occasional (29-5%)
41 infertility 58 Occasional (29-5%)
42 premature birth 58 Very rare (<4-1%)
43 impaired proprioception 58 Occasional (29-5%)
44 lymphadenopathy 58 Frequent (79-30%)
45 impotence 58 Occasional (29-5%)
46 choreoathetosis 58 Occasional (29-5%)
47 hemiparesis 58 Occasional (29-5%)
48 diplopia 58 Occasional (29-5%)
49 diarrhea 58 Occasional (29-5%)
50 sensory impairment 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Sleeping Sickness according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.75 NOS2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.75 H2AC18 NOS2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.75 NOS2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-136 9.75 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.75 H2AC18 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.75 H2AC18
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-168 9.75 H2AC18
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 9.75 ODC1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.75 NOS2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 9.75 PRODH
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.75 ODC1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.75 PRODH
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.75 PRODH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.75 H2AC18
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 9.75 PRODH
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.75 H2AC18
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 9.75 H2AC18
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 9.75 NOS2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-5 9.75 PRODH
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 9.75 NOS2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.75 PRODH
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.75 NOS2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.75 PRODH
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-99 9.75 NOS2 ODC1

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
2 Nifurtimox Investigational Phase 3 23256-30-6
3 Melarsoprol Investigational Phase 3 494-79-1
4 Immunoglobulins Phase 2, Phase 3
5 Antibodies Phase 2, Phase 3
6 polysaccharide-K Phase 2, Phase 3
7 Anti-Infective Agents Phase 3
8 Antiprotozoal Agents Phase 3
9 Antiparasitic Agents Phase 3
10
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
11
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Permethrin Approved, Investigational Phase 2 52645-53-1 40326
14
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
15
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
16
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
17
Pafuramidine Investigational Phase 2 186953-56-0
18 Antifungal Agents Phase 2
19 Insect Repellents Phase 2
20 Trace Elements Phase 2
21 Micronutrients Phase 2
22 Vitamins Phase 2
23 Antioxidants Phase 2
24 Nutrients Phase 2
25 Protective Agents Phase 2
26
Methylphenidate Approved, Investigational 113-45-1 4158
27
Modafinil Approved, Investigational 68693-11-8 4236
28
Caffeine Approved 58-08-2 2519
29
Dopamine Approved 51-61-6, 62-31-7 681
30 Immunoglobulins, Intravenous
31 Immunologic Factors
32 Immunoglobulin M
33 Immunoglobulin G
34 Dopamine Agents
35 Central Nervous System Stimulants
36 Phosphodiesterase Inhibitors
37 Neurotransmitter Agents

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
3 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
4 Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
5 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
6 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
7 Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial Recruiting NCT03974178 Phase 2, Phase 3 Fexinidazole
8 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Recruiting NCT04099628 Phase 2, Phase 3
9 Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study Active, not recruiting NCT03087955 Phase 2, Phase 3 Acoziborole (SCYX-7158)
10 An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Active, not recruiting NCT03025789 Phase 3 Fexinidazole
11 Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
12 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
13 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
14 Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
15 Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
16 A Within-subject Laboratory and Field Trial to Test the Use of Commercially Available Insect Repellents Against Contact From Musca Sorbens, the Putative Vector of Trachoma Completed NCT03813069 Phase 2
17 Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia Terminated NCT00184054 Phase 2 Arsenic Trioxide (ATO);Ascorbic Acid
18 Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers Completed NCT00982904 Phase 1 Fexinidazole/Placebo
19 Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers Completed NCT01340157 Phase 1 Fexinidazole
20 A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition Completed NCT02571062 Phase 1 Fexinidazole
21 Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers Completed NCT01533961 Phase 1 SCYX-7158;Placebo
22 An Open Label, Single-dose, Single Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-Acoziborole Recruiting NCT04270981 Phase 1 [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
23 Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers. Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
24 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
25 Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study Completed NCT02071615 Methylphenidate 20 mg tablet given once by mouth;modafinil 200mg tablet given once by mouth;caffein 200mg tablet given once by mouth;placebo
26 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
27 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Recruiting NCT03356665
28 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure Active, not recruiting NCT03112655
29 Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria Not yet recruiting NCT03394976

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Eflornithine
Eflornithine Hydrochloride

Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

40
Testes, Brain, Eye, T Cells, Heart, Kidney, B Cells

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 4302)
# Title Authors PMID Year
1
Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. 54 61
20220141 2010
2
Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. 61 54
19748525 2010
3
Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. 54 61
17643344 2007
4
Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase. 61 54
17615587 2007
5
Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. 61 54
17610127 2007
6
A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. 54 61
17407445 2007
7
Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. 54 61
17504214 2007
8
In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei. 61 54
16896212 2006
9
The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness. 54 61
15217727 2004
10
The detection of bovine lactoferrin binding protein on Trypanosoma brucei. 54 61
15240935 2004
11
Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. 54 61
12805119 2003
12
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 61 54
12653650 2003
13
Transferrin coupled azanthraquinone enhances the killing effect on trypanosomes. The role of lysosomal mannosidase. 54 61
12514955 2002
14
Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei. 54 61
10713060 2000
15
The transferrin receptor of Trypanosoma brucei. 61 54
11227758 2000
16
Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. 54 61
9822549 1998
17
Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. 54 61
9174360 1997
18
Synthesis and structure-activity relationships of analogs of 2'-deoxy-2'-(3-methoxybenzamido)adenosine, a selective inhibitor of trypanosomal glycosomal glyceraldehyde-3-phosphate dehydrogenase. 61 54
7562915 1995
19
Polyamines as targets for therapeutic intervention. 54 61
7598507 1995
20
Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. 54 61
7932587 1994
21
Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. 54 61
8347171 1993
22
2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. 61
32074064 2020
23
Diversity of trypanosomes in wildlife of the Kafue ecosystem, Zambia. 61
32420023 2020
24
Single-strand conformation polymorphism (SSCP) of mitochondrial genes helps to estimate genetic differentiation, demographic parameters and phylogeny of Glossina palpalis palpalis populations from West and Central Africa. 61
32247869 2020
25
Role of the translocase of the mitochondrial inner membrane in the import of tRNAs into mitochondria in Trypanosoma brucei. 61
32339625 2020
26
The large repertoire of 2'-O-methylation guided by C/D snoRNAs on Trypanosoma brucei rRNA. 61
32250712 2020
27
In-silico identification of fingerprint of pyrazolyl sulfonamide responsible for inhibition of N-myristoyltransferase using Monte Carlo method with index of ideality of correlation. 61
32579066 2020
28
Trypanosomes have divergent kinesin-2 proteins that function differentially in flagellum biosynthesis and cell viability. 61
32503938 2020
29
Validation of ligands targeting metacaspase-2 (MCA2) from Trypanosoma brucei brucei and their application to MCA5 from T. congolense as possible trypanocides. 61
32197135 2020
30
Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense. 61
32329206 2020
31
High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor. 61
32496217 2020
32
Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT. 61
32354566 2020
33
Structure-activity relationship exploration of 3'-deoxy-7-deazapurine nucleoside analogues as anti-Trypanosoma brucei agents. 61
32568511 2020
34
Ribose-5-phosphate isomerases: characteristics, structural features, and applications. 61
32533303 2020
35
Fragment-based discovery of non-bisphosphonate binders of Trypanosoma brucei farnesyl pyrophosphate synthase. 61
32537808 2020
36
A review of the systematics, species identification and diagnostics of the Trypanosomatidae using the maxicircle kinetoplast DNA: from past to present. 61
32333942 2020
37
When, Who, and How to Sample: Designing Practical Surveillance for 7 Neglected Tropical Diseases as We Approach Elimination. 61
32529261 2020
38
Neglected Tropical Diseases in the Context of Climate Change in East Africa: A Systematic Scoping Review. 61
32228798 2020
39
Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes. 61
32354742 2020
40
Use of herbal remedies in the management of sleeping sickness in four northern provinces of Angola. 61
31743767 2020
41
Screening Strategies for a Sustainable Endpoint for Gambiense Sleeping Sickness. 61
31876949 2020
42
Substrate promiscuity of polyketide synthase enables production of tsetse fly attractants 3-ethylphenol and 3-propylphenol by engineering precursor supply in yeast. 61
32561880 2020
43
The function of Apolipoproteins L (APOLs): relevance for kidney disease, neurotransmission disorders, cancer and viral infection. 61
32530132 2020
44
Trypanosome infections in naturally infected horses and donkeys of three active sleeping sickness foci in the south of Chad. 61
32576240 2020
45
Uncertainty and sensitivity analyses of extinction probabilities suggest that adult female mortality is the weakest link for populations of tsetse (Glossina spp). 61
32392220 2020
46
Nanotechnological interventions for treatment of trypanosomiasis in humans and animals. 61
32383004 2020
47
Phosphoproteomic analysis of mammalian infective Trypanosoma brucei subjected to heat shock suggests atypical mechanisms for thermotolerance. 61
32198071 2020
48
Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. 61
32437391 2020
49
Identifying Cattle Breed-Specific Partner Choice of Transcription Factors during the African Trypanosomiasis Disease Progression Using Bioinformatics Analysis. 61
32456126 2020
50
Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense. 61
32435388 2020

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to KEGG:

36
# Name Kegg Source Accession
1 African trypanosomiasis hsa05143

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 TF IL6 IL10 HSPA8 HPR HP
2 extracellular space GO:0005615 9.81 TF IL6 IL10 HSPA8 HPR HP
3 extracellular exosome GO:0070062 9.65 TF PGD HSPA8 HPR HP H2AC18
4 spherical high-density lipoprotein particle GO:0034366 9.26 HPR APOA1
5 blood microparticle GO:0072562 9.1 TF HSPA8 HPR HP APOL1 APOA1

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.8 NOS2 IL10 HP CXCL13
2 cellular protein metabolic process GO:0044267 9.76 TF IL6 APOL1 APOA1
3 cellular response to lipopolysaccharide GO:0071222 9.73 NOS2 IL6 IL10 CXCL13
4 response to organic substance GO:0010033 9.7 IL10 HPR HP
5 receptor-mediated endocytosis GO:0006898 9.62 HPR HP APOL1 APOA1
6 positive regulation of cell death GO:0010942 9.54 PRODH HPR HP
7 acute inflammatory response GO:0002526 9.51 HPR HP
8 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.48 IL10 APOA1
9 negative regulation of cytokine production involved in immune response GO:0002719 9.4 IL10 APOA1
10 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 IL10 APOA1
11 spermidine biosynthetic process GO:0008295 9.16 SRM AMD1
12 polyamine biosynthetic process GO:0006596 9.13 SRM ODC1 AMD1
13 polyamine metabolic process GO:0006595 8.8 SRM ODC1 AMD1

Molecular functions related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemoglobin binding GO:0030492 8.96 HPR HP
2 NADP binding GO:0050661 8.92 PGD NOS2 GSR GAPDH

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....